The research addresses one of the most persistent frustrations in Alzheimer’s science: although decades of work have catalogued the plaques of amyloid-beta protein and tangles of tau that accumulate in diseased brains, the molecular mechanisms that translate these pathological hallmarks into progressive cognitive decline remain poorly understood, and effective therapies remain stubbornly absent. The team behind the new work reasoned that part of the answer might lie not in the protein-coding genes alone, but in the vast, once-dismissed “dark matter” of the genome—the non-coding RNAs that now appear to act as master conductors of gene expression.

At the heart of the study is a concept known as competing endogenous RNA, or ceRNA. The logic is elegantly simple. MicroRNAs, or miRNAs, are short RNA molecules that bind to messenger RNAs—the instructions from which proteins are built—and suppress their translation or mark them for destruction. But circular RNAs and long non-coding RNAs can carry binding sites for the same miRNAs. When these non-coding transcripts are abundant, they act as molecular sponges, mopping up miRNAs and thereby freeing messenger RNAs to produce their proteins. The result is a complex communication network in which thousands of transcripts indirectly regulate one another by competing for a limited pool of miRNA inhibitors. Disruptions to this network, the researchers hypothesized, could lie upstream of the catastrophic inflammation seen in Alzheimer’s brains.

To test this, the team performed whole-transcriptome sequencing on hippocampal tissue from APP/PS1 transgenic mice, a widely used model in which mice carry human genes for mutant amyloid precursor protein and presenilin 1, driving the formation of amyloid plaques and memory impairment that resemble the human disease. The sequencing effort was exhaustive. When the researchers compared the diseased animals to healthy controls, they found 376 differentially expressed messenger RNAs, 491 long non-coding RNAs, 5,253 circular RNAs, and 21 microRNAs whose levels had shifted significantly. The sheer scale of the circular RNA signal—more than five thousand distinct circRNA species altered in the diseased hippocampus—underscores how dynamic this class of molecules is in neurodegeneration.

These thousands of altered transcripts were then integrated computationally into ceRNA networks, with predictions of which molecules could plausibly bind one another based on complementary seed sequences. Functional enrichment analysis using the Gene Ontology and KEGG pathway databases revealed that the genes embedded in these networks clustered with striking consistency around pathways of programmed cell death—encompassing NF-κB inflammatory signaling and the assembly of molecular complexes known as inflammasomes. This was a crucial clue. Neuroinflammation, driven largely by activated microglial cells, the brain’s resident immune cells, is increasingly recognized not as a mere byproduct of Alzheimer’s disease but as an active driver of neuronal loss.

From the tangle of predicted interactions, one axis rose above the rest: circular RNA 13083, microRNA-298-5p, and the messenger RNA for CD14, a receptor well known to immunologists for its role in recognizing bacterial components and amplifying inflammatory responses. In the ceRNA framework, circRNA_13083 acts as a sponge for miR-298-5p. When the circular RNA is abundant, it sequesters the microRNA, allowing CD14 messenger RNA to be translated freely and CD14 protein levels to climb. The researchers’ computational predictions placed this axis at a key regulatory node within the disease-associated network, and laboratory validation followed.

In vitro experiments using both microglial and neuronal models of Alzheimer’s disease confirmed that CD14 expression is elevated in the diseased state. The team then used small interfering RNAs to deliberately knock down CD14 and observed what happened when cells were exposed to aggregated amyloid-beta 1-42, the toxic peptide that accumulates in Alzheimer’s plaques. The results were striking. Silencing CD14 significantly attenuated the activation of NF-κB, a transcription factor that functions as a master switch for inflammation. It also reduced the assembly of the NLRP3 inflammasome, a multi-protein machine that, when triggered, activates caspase-1 and drives the maturation and secretion of two of the most potent pro-inflammatory signaling molecules in the brain: interleukin-1 beta and interleukin-18.

Quantitative real-time PCR confirmed the changes in gene expression for CD14, components of the NF-κB pathway, and markers of the NLRP3 inflammasome, while enzyme-linked immunosorbent assays quantified the drop in secreted IL-1β and IL-18 protein. But perhaps the most compelling evidence came from a series of conditioned medium transfer experiments. The researchers collected the liquid environment in which microglia had been grown—with or without CD14 silencing—and applied it to healthy HT-22 neuronal cells. Medium from amyloid-stimulated microglia with intact CD14 damaged the neurons; medium from microglia in which CD14 had been knocked down allowed significantly improved HT-22 cell survival, measured by CCK-8 viability assays. In other words, CD14 was not merely a marker of inflammation but a functional conduit through which activated microglia inflict harm on their neuronal neighbors.

The findings position CD14 as a potential therapeutic target in Alzheimer’s disease, an appealing proposition given that the gene sits at the intersection of several pathological processes. By promoting CD14 expression through the ceRNA mechanism, dysregulated circular RNAs like circRNA_13083 may tip the balance toward chronic microglial activation, inflammasome-driven cytokine release, and the programmed cell death of neurons. Interruption of this cascade at the CD14 node simultaneously dampens NF-κB signaling, prevents NLRP3 inflammasome assembly, reduces inflammatory cytokine output, and shields neurons from microglia-mediated toxicity. Whether the same dynamics operate in human brains, and whether CD14 can be safely modulated in patients, are questions that will require substantial further work, and the authors are careful to describe the axis as “potentially implicated” rather than definitively proven in human disease.

The study also carries broader methodological significance. Whole-transcriptome sequencing, by capturing messenger RNAs, long non-coding RNAs, circular RNAs, and microRNAs in a single experimental pass, allows researchers to view the cell’s regulatory circuitry as an integrated whole rather than in fragments. The extensive ceRNA networks reconstructed here—spanning thousands of circular and long non-coding RNAs interacting with dozens of microRNAs to shape the expression of hundreds of protein-coding genes—suggest that Alzheimer’s disease involves a system-wide rewiring of post-transcriptional regulation, not merely the altered expression of a handful of culprit genes. Such network-level views may help explain why single-target drug approaches have repeatedly fallen short in clinical trials for the disease.

All experimental procedures were approved by the institutional animal ethics committee and conducted in accordance with national guidelines for laboratory animal care and the ARRIVE recommendations. The work was supported by the National Natural Science Foundation of China and the Tianjin Science and Technology program. The team, led by corresponding author Yuan Ma and including co-first authors KeFei Duan, Fangfang Zhan, Yaodan Zhang and Xinghang Wang from institutions spanning Beijing, Fujian, Guangzhou, Henan, and Chifeng, has made the article open access, allowing researchers worldwide to mine the transcriptomic datasets and network predictions for new therapeutic hypotheses.

As the search for Alzheimer’s treatments continues, studies like this one highlight a shift in strategy: away from attacking plaques and tangles in isolation and toward understanding the regulatory networks that govern how brain cells respond to them. If a single immune receptor such as CD14 can be shown to sit at a critical junction in that network—connecting circular RNAs, microRNAs, inflammatory signaling, and neuronal survival—it may offer a point of intervention that is both biologically grounded and, with the rise of RNA-based therapeutics, increasingly within technological reach.

Alzheimer’s disease, a neurodegenerative disorder affecting millions globally, remains a formidable challenge due to its complex etiology and elusive molecular underpinnings. The latest study ventures beyond traditional neuropathological analyses by harnessing transcriptomic data derived from post-mortem human brain tissues alongside three-dimensional brain organoids—miniature, lab-grown models that recapitulate human brain microenvironments. This dual approach allowed the researchers to capture the nuanced gene expression patterns reflective of in vivo conditions and experimental manipulations, providing a holistic view of gene dysregulation in AD.

Central to their findings is the pivotal role of receptor tyrosine kinases, a class of enzymes integral to cell signaling, growth, and differentiation. Dysregulation of RTK pathways has long been suspected in neurodegenerative processes, but this study delineates how specific RTKs contribute to neuroinflammation, synaptic dysfunction, and neuronal death associated with Alzheimer’s. The data suggest that aberrant RTK signaling cascades may instigate a vicious cycle of cellular stress and neurodegeneration, reinforcing the complexity of AD pathology.

Employing single-cell and bulk RNA sequencing technologies, the researchers mapped the expression profiles of thousands of genes, uncovering distinct genetic signatures that differentiate AD brains from healthy controls. Among these, several gene clusters linked to immune responses, oxidative stress, and metabolic dysregulation were identified, corroborating existing theories about inflammation and mitochondrial dysfunction in Alzheimer’s pathology. The integration of transcriptomic landscapes from organoids enriched the understanding by modeling disease-relevant cellular interactions and temporal progression.

One of the most compelling aspects of this study is its use of human brain organoids derived from induced pluripotent stem cells (iPSCs), which were genetically engineered to harbor Alzheimer’s-associated mutations. This innovative model system replicated hallmark features of AD, such as amyloid-beta plaque formation and tauopathy, thereby validating its utility as a proxy for human brain tissue. The organoid transcriptomes unveiled early molecular shifts preceding overt pathological signs, offering a window into the presymptomatic phases of the disease.

The elucidation of RTK pathway alterations also identified potential molecular targets for drug development. The study highlights several RTK family members whose upregulation correlates with synaptic degradation and microglial activation, implicating them as critical nodes in the AD molecular network. Targeting these kinases with small molecule inhibitors or monoclonal antibodies could modulate disease progression, paving the way for precision therapies tailored to individual genetic profiles.

Beyond the biological revelations, the study underscores the power of integrative multi-omics and advanced modeling to decode complex brain disorders. By combining human data with organoid models, the research exemplifies how translational neuroscience can transcend traditional species limitations and yield mechanistic insights directly relevant to human disease phenotypes. This refined approach offers a blueprint for future investigations into other neurodegenerative conditions like Parkinson’s and frontotemporal dementia.

The implications of these findings extend into biomarker discovery, as the identified gene signatures could serve as diagnostic or prognostic indicators. Early detection of Alzheimer’s remains a clinical hurdle; thus, transcriptomic markers detected in accessible tissues or biofluids could revolutionize screening protocols. Furthermore, understanding RTK-driven pathways may aid in stratifying patients who would benefit most from targeted interventions, enhancing personalized medicine strategies in neurology.

However, the authors caution that while organoid models recapitulate many aspects of human brain physiology, limitations remain. The absence of full vascularization and peripheral immune components constrains the ability to mimic systemic influences on Alzheimer’s progression fully. Nonetheless, the study’s meticulous design and robust data establish a compelling framework for iterative refinements in organoid technology and its applications in neurodegenerative disease research.

As Alzheimer’s disease continues to pose an escalating global health crisis, the urgency for effective treatments intensifies. This study’s integration of transcriptomic datasets from both human brains and genetically precise organoids furnishes a holistic molecular atlas of Alzheimer’s pathology, illuminating previously uncharted signaling networks. By highlighting the nuanced interplay between RTK pathways and genetic dysregulation, the research inspires hope for novel interventions that curtail or even reverse disease trajectories.

Looking forward, the research team plans to expand this line of inquiry by incorporating longitudinal analyses of organoid development under varying genetic and environmental conditions. Such studies could elucidate how early life exposures and genetic predispositions converge to initiate and propagate Alzheimer’s pathology. Moreover, leveraging CRISPR-Cas9 genome editing in organoids to modulate RTK-related genes may validate therapeutic targets and accelerate drug testing pipelines.

This research epitomizes the cutting edge of neuroscience and molecular biology, demonstrating how sophisticated experimental systems coupled with high-resolution transcriptomics can dissect the complexities of human brain diseases. The bridging of human tissue analyses with functional organoid modeling sets a new standard for neurodegenerative research, fostering interdisciplinary collaborations and catalyzing innovation in drug discovery.

In sum, the comprehensive transcriptomic profiling of Alzheimer’s disease brain tissues alongside human-derived organoids shines a spotlight on receptor tyrosine kinase pathways as fundamental drivers of pathology. This insight reshapes our conceptualization of AD, emphasizing the necessity to broaden therapeutic focus beyond traditional amyloid-centric paradigms. As the field advances, this study’s rich molecular data will undoubtedly fuel the quest for breakthroughs in diagnosing and treating one of the most daunting challenges in modern medicine.

Subject of Research: The study focuses on uncovering the molecular mechanisms of Alzheimer’s disease by analyzing transcriptomic data from human brain tissues and brain organoids, with an emphasis on receptor tyrosine kinase pathways and disease-associated genetic signatures.

Article Title: Human brain and organoid transcriptomes reveal key receptor tyrosine kinase pathways and genetic signatures in Alzheimer’s disease.

Article References:
Shin, S., Zhu, X., Amartumur, S. et al. Human brain and organoid transcriptomes reveal key receptor tyrosine kinase pathways and genetic signatures in Alzheimer’s disease. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01684-5

Image Credits: AI Generated

DOI: 15 April 2026